TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01663701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified severe sepsis protocol
Description: This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients are managed according to admitting doctors' orders
Study: NCT02881112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Therapy System
Description: Treatment with the Provant Therapy System
Study: NCT04088084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmitoylethanolamide (PEA) 600 mg
Description: PEA 600 mg was added to topical therapy
Study: NCT02545114

Intervention type: DRUG
Group type: OTHER
Intervention: Tolvaptan
Description: Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
Study: NCT02649374

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary, Exercise and lifestyle modifications
Description: Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
Study: NCT00278369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
Study: NCT04218838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CornerLoc SI Joint Stabilization Procedure
Description: CornerLoc minimally invasive SI Joint Stabilization System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Sacroiliac Joint Steroid Injection
Description: Standard of Care - Steroid injection into the sacroiliac joint
Study: NCT02085096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Problem-Solving Therapy
Description: Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
Study: NCT01824329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate capsule sparing cystectomy
Description: Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve sparing cystectomy
Description: Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
Study: NCT03657563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive psychological intervention
Description: Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available.
Study: NCT01824901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Given PO
Study: NCT00607412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated psychotherapy for PTSD and substance use
Description: integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-step based supportive therapy
Description: supportive psychotherapy based on 12-step model
Study: NCT00844051

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: School-based influenza vaccination program
Description: School-based influenza vaccination program
Study: NCT01365234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing Lead
Description: Implant and follow up of Model 20066 lead
Study: NCT03468816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor activation (on DryMax Extra Soft)
Description: Study profile of sensor activation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor activation (on DryMax Extra Soft)
Description: Study profile of sensor activation
Study: NCT05966428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercises
Description: This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy
Description: The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group.
Study: NCT01297361

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood sampling for diagnosis of vitamins deficiencies
Study: NCT03511625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Injectable Product
Description: Acthar is a non-specific melanocortin receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo medrol
Description: Depo medrol is an anti-inflammatory glucocorticoid
Study: NCT03049267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
Study: NCT00701142

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemocomplettan® P
Description: Single intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Single intravenous infusion
Study: NCT04610489

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quidel Sofia SARS Antigen FIA
Description: Obtained via bilateral mid-turbinate swab.
Study: NCT01174004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimavanserin tartrate
Description: pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, tablet, once daily by mouth for 6 weeks
Study: NCT02520050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional MNT
Description: Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
Study: NCT01360372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone
Description: Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline 0.4 to 0.8 ml injection
Study: NCT02520050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured MNT
Description: Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured MNT plus Weekly Support
Description: Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
Study: NCT02050074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01352689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828(FDC)
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
Study: NCT02552563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Care Management
Description: The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
Study: NCT00429273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPH)
Description: Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Description: Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
Study: NCT03211689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
Study: NCT03773679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily Exercise
Description: Daily Exercise Programme
Study: NCT01955434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study: NCT03921086

Intervention type: DRUG
Group type: OTHER
Intervention: Antihypertensive medication according to the study's algorithm
Description: Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm.
Study: NCT02599272

Intervention type: OTHER
Group type: OTHER
Intervention: Rice with tomatoes and peeled aubergine (no spice)
Description: Dose 0

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with vegetables and low spice
Description: Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with vegetables and high spice
Description: Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
Study: NCT03398395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrown restoration
Description: a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 90° shoulder endocrown restoration
Description: a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
Study: NCT01955434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01438957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Description: Dexmedetomidine 0.2 to 0.7 mcg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Description: Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
Study: NCT01955434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smac Mimetic LCL161
Description: Given PO
Study: NCT00394901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
Study: NCT00394901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
Study: NCT01438957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02634684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextroamphetamine
Description: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study: NCT03697499

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fish oil and acute ozone exposure
Description: The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: fish oil and sham exposure
Description: The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: soy oil and acute ozone exposure
Description: The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: soy oil and sham exposure
Description: The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
Study: NCT01209455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorphenamine and Ranitidine
Description: We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
Study: NCT04070326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
Study: NCT01886690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based new eye drop formulation
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based eye drops
Description: 1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.